Jinwon Life Sciences Confirms Virus Reduction After Using COVID-19 Cosplay Treatment

[Asia Economy Reporter Jang Hyowon] GeneOne Life Science announced on the 18th that GLS-1200, a nasal spray treatment for preventing infection of the novel coronavirus disease (COVID-19), was confirmed to reduce the COVID-19 virus in the nasal area and inhibit infection within nasal cells through a ferret infection animal model.

According to the company, after administering GLS-1200 5 minutes before and 24 hours after injecting the COVID-19 virus into the ferret's nasal area, PCR tests for the COVID-19 virus were conducted 3 days later. The results showed that 83% of the control group, which did not receive GLS-1200 treatment, tested positive, whereas only 17% of the GLS-1200 treated group tested positive. It was confirmed that the COVID-19 virus in the nasal turbinate area decreased 12-fold compared to the control group.

Park Younggeun, CEO of GeneOne Life Science, stated, “Through this animal experiment, we confirmed an outstanding reduction of the COVID-19 virus in the nasal area as a nasal spray treatment,” and added, “GLS-1200 has excellent potential as a treatment to prevent COVID-19 virus infection.”

Meanwhile, GeneOne Life Science is conducting a Phase 2 clinical trial of the COVID-19 infection prevention nasal spray treatment GLS-1200 in the United States.

This content was produced with the assistance of AI translation services.